Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – FDA authorises Becton Dickinson’s Covid-19 combination test – GenScript receives FDA EUA to use cPass test in convalescent plasma screening

15 Feb 2021 (Last Updated February 15th, 2021 09:59)

Becton Dickinson has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for a molecular test that can identify Covid-19 and influenza. The BD SARS-CoV-2/Flu test can deliver results within two to three hours and can detect both the UK and South Africa variants.

GenScript has been granted EUA for its cPass SARS-CoV-2 neutralisation antibody detection kit in convalescent plasma screening. The cPass test kit is the first FDA authorised test that detects Covid-19 neutralising antibodies without using the live virus.

Indonesia is now using rapid antigen tests as an first step when screening for Covid-19, to try and accelerate the rate of detection and reduce disease transmission. The Indonesian government is now distributing two million rapid antigen tests throughout the country. While PCR testing has better sensitivity and specificity, Indonesia’s laboratories are few in number and located primarily in big cities, meaning rural regions have been facing waiting times on PCR test of more than a week.